Gratus Capital LLC Allogene Therapeutics, Inc. Transaction History

Gratus Capital LLC

  • $2.39 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 03, 2022
BUY
$10.32 - $17.28 $249,465 - $417,709
24,173 Added 11.3%
238,159 $2.57 Million
Q2 2022

Jul 29, 2022
BUY
$6.78 - $12.28 $78,281 - $141,784
11,546 Added 5.7%
213,986 $2.44 Million
Q1 2022

Apr 29, 2022
BUY
$7.65 - $15.29 $80,852 - $161,600
10,569 Added 5.51%
202,440 $1.84 Million
Q4 2021

Jan 31, 2022
BUY
$13.13 - $24.52 $2.52 Million - $4.7 Million
191,871 New
191,871 $2.86 Million

Others Institutions Holding ALLO

# of Institutions
165
Shares Held
134M
Call Options Held
59.4K
Put Options Held
113K
View Full List

About Allogene Therapeutics, Inc.

ALLO Quotes by TradingView
  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $279M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Gratus Capital LLC Portfolio

Follow Gratus Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gratus Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gratus Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email